Skip to main content
Premium Trial:

Request an Annual Quote

Swift Biosciences SARS-CoV-2 Research Panel

Swift Biosciences has released a research-use targeted sequencing panel for SARS-CoV-2. The amplicon-based multiplex panel targets the full 30 kb viral genome in a single tube, two-hour workflow with two rounds of PCR. More than three hundred primer pairs help increase sensitivity and specificity due to the higher probability of amplifying limited quantities of viral template material, as does the ability to use sequencing to confirm that reads are mappable to SARS-CoV-2 instead of similar coronaviruses or pathogens, the company said. Swift's workflow also adds sequencing adapters directly without the need for a secondary library construction.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.